AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27816302 — intervention group
Group type: EXPERIMENTAL
Intervention: Central airways obstruction (CAO) defined by FEV1/FVC <0.7
Number of subjects: 585
Study 27816302 — intervention group
Group type: EXPERIMENTAL
Intervention: Small airways obstruction (SAO) defined by FEV1/FVC ≥0.7 plus MEF <60% of predicted value
Number of subjects: 585
Study 27816302 — intervention group
Group type: COMPARATOR
Intervention: No airways obstruction
Number of subjects: 585
Study 24788581 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Stimulation group Therapy (MST)
Number of subjects: 60
Study 23378471 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.36% glucose during the day and 1 overnight exchange of 1.36% glucose
Number of subjects: 83
Study 23378471 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.36% glucose during the day and 1 overnight exchange of 2.27% glucose
Number of subjects: 83
Study 23378471 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.36% glucose during the day and 1 overnight exchange of 3.86% glucose
Number of subjects: 83
Study 21397096 — intervention group
Group type: EXPERIMENTAL
Intervention: PCB plus 10% lidocaine spray
Number of subjects: 77
Study 21397096 — intervention group
Group type: COMPARATOR
Intervention: Paracervical blocks (PCB)
Number of subjects: 77
Study 18310675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine gargle (40 mg in saline 30 ml)
Number of subjects: 46
Study 18310675 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 30 ml)
Number of subjects: 46
Study 17062365 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF 1 L/min with 1% isoflurane
Number of subjects: 60
Study 17062365 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF 2 L/min with 1% isoflurane
Number of subjects: 60
Study 17062365 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF 3 L/min with 1% isoflurane
Number of subjects: 60
Study 17062365 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF 1 L/min with 2% isoflurane
Number of subjects: 60
Study 17062365 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF 2 L/min with 2% isoflurane
Number of subjects: 60
Study 17062365 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF 3 L/min with 2% isoflurane
Number of subjects: 60
Study 17062365 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 60
Study 17062365 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 60
Study 12150370 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral breathing
Number of subjects: 20
Study 12150370 — intervention group
Group type: COMPARATOR
Intervention: Nasal breathing
Number of subjects: 20
Study 10433004 — intervention group
Group type: COMPARATOR
Intervention: Fasting conditions
Number of subjects: 26
Study 10433004 — intervention group
Group type: COMPARATOR
Intervention: Postprandial conditions
Number of subjects: 26
Study 10433004 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 26
Study 7748687 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal Early Discharge and Family Support Programme (NEDP)
Number of subjects: 0
Study 7748687 — intervention group
Group type: EXPERIMENTAL
Intervention: NEDP
Number of subjects: 0
Study 2124470 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg once a day
Number of subjects: 21
Study 2124470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 373792 — intervention group
Group type: EXPERIMENTAL
Intervention: Loestrin-20 (20 microgram ethinyl oestradiol and 1 mg norethisterone acetate)
Number of subjects: 55
Study 373792 — intervention group
Group type: COMPARATOR
Intervention: Microgynon-30 (30 microgram ethinyl oestradiol and 150 microgram levonorgestrel)
Number of subjects: 55
Study 373792 — intervention group
Group type: EXPERIMENTAL
Intervention: Loestrin-20
Number of subjects: 55
Study 373792 — intervention group
Group type: COMPARATOR
Intervention: Microgynon-30
Number of subjects: 55
Study 6365466 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide 3 mg per day
Number of subjects: 90
Study 6365466 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide 6 mg per day
Number of subjects: 90
Study 6365466 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide 12 mg per day
Number of subjects: 90
Study 6365466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 31022160 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (IL‐I) with increased physical activity and reduced caloric intake, more frequent external support than control group.
Number of subjects: 0
Study 31022160 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (IL‐I)
Number of subjects: 0
Study 31022160 — intervention group
Group type: COMPARATOR
Intervention: Control group (less frequent external support)
Number of subjects: 0
Study 31022160 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29158143 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg Tobrate™
Number of subjects: 9
Study 28128758 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-osmolar iodinated contrast media (770 mOsm/kg H2O - Group 1)
Number of subjects: 16
Study 28128758 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso-osmolar iodinated contrast media (290 mOsm/kg H2O - Group 2)
Number of subjects: 16
Study 24419562 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea (700 ml/day for 14 days)
Number of subjects: 10
Study 22748970 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole granules mixed with soft food or infant formula (10 mg)
Number of subjects: 35
Study 22748970 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole suspension with inactive vehicle granules (reference)
Number of subjects: 35
Study 22748970 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment-emergent adverse events (TEAEs)
Number of subjects: 35
Study 21131038 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 239
Study 21131038 — intervention group
Group type: COMPARATOR
Intervention: Idarubicin
Number of subjects: 239
Study 17494097 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (T) gel (100 mg/d) plus depomedroxyprogesterone acetate (300 mg intramuscularly every 12 weeks) with GnRH antagonist acyline (300 microg/kg subcutaneously every 2 weeks for 12 weeks)
Number of subjects: 20
Study 17494097 — intervention group
Group type: COMPARATOR
Intervention: Transdermal testosterone (T) gel (100 mg/d) plus depomedroxyprogesterone acetate (300 mg intramuscularly every 12 weeks) without GnRH antagonist acyline
Number of subjects: 20
Study 15737074 — intervention group
Group type: EXPERIMENTAL
Intervention: Iterative partial least squares based on the Buckley-James estimating equation
Number of subjects: 0
Study 15737074 — intervention group
Group type: COMPARATOR
Intervention: Other dimension reduction techniques
Number of subjects: 0
Study 11972294 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Volume Expansion (PVX) using Dextran [6 %] or Pentaspan [10 %] (6.7 ml/kg)
Number of subjects: 8
Study 11972294 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Volume Expansion (PVX)
Number of subjects: 8
Study 9918907 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 25 mg orally once daily for 1 week
Number of subjects: 70
Study 9918907 — intervention group
Group type: COMPARATOR
Intervention: Control (no losartan)
Number of subjects: 70
Study 8525398 — intervention group
Group type: COMPARATOR
Intervention: IVER 100
Number of subjects: 43
Study 8525398 — intervention group
Group type: EXPERIMENTAL
Intervention: IVER 400
Number of subjects: 43
Study 2178724 — intervention group
Group type: EXPERIMENTAL
Intervention: Uro-Vaxom (UV)
Number of subjects: 120
Study 2178724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 232563 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (7.5, 15, 30 mg/70 kg)
Number of subjects: 7
Study 232563 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (10 or 20 mg/70 kg)
Number of subjects: 7
Study 232563 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin (3, 6, 12 mg/70 kg)
Number of subjects: 7
Study 232563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31944801 — intervention group
Group type: EXPERIMENTAL
Intervention: More Appreciation (MA) intervention
Number of subjects: 803
Study 31944801 — intervention group
Group type: EXPERIMENTAL
Intervention: Less Criticism (LC) intervention
Number of subjects: 803
Study 31944801 — intervention group
Group type: COMPARATOR
Intervention: Fruit and Vegetable (FV) control arm
Number of subjects: 803
Study 31944801 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms (MA, LC, FV)
Number of subjects: 803
Study 30885157 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of ivermectin and albendazole
Number of subjects: 600
Study 30885157 — intervention group
Group type: COMPARATOR
Intervention: Albendazole monotherapy (control)
Number of subjects: 600
Study 29631920 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-guided self-help intervention for common mental health difficulties
Number of subjects: 27
Study 26763343 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 0
Study 26763343 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pessary)
Number of subjects: 0
Study 25045908 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation-phase cognitive therapy (C-CT)
Number of subjects: 241
Study 25045908 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 241
Study 25045908 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 241
Study 25045908 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (C-CT, FLX, and placebo)
Number of subjects: 241
Study 22640673 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonconventional elastomeric ligatures
Number of subjects: 20
Study 22640673 — intervention group
Group type: COMPARATOR
Intervention: Conventional elastomeric ligatures
Number of subjects: 20
Study 20306476 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcitriol 0.25 mcg twice daily for 1 week, followed by oral calcitriol 0.50 mcg twice daily for 1 week
Number of subjects: 9
Study 20306476 — intervention group
Group type: COMPARATOR
Intervention: Healthy age-matched controls
Number of subjects: 9
Study 17416125 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-body stretch
Number of subjects: 54
Study 17416125 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeper stretch
Number of subjects: 54
Study 17416125 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stretching)
Number of subjects: 54
Study 16387087 — intervention group
Group type: COMPARATOR
Intervention: Thymoglobulin
Number of subjects: 196
Study 16387087 — intervention group
Group type: COMPARATOR
Intervention: Campath 1H
Number of subjects: 196
Study 16387087 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-free low-dose tacrolimus immunosuppressive monotherapy
Number of subjects: 196
Study 12553382 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic tube compensation (30 minutes)
Number of subjects: 12
Study 12553382 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support (7 cmH2O, 30 minutes)
Number of subjects: 12
Study 12553382 — intervention group
Group type: COMPARATOR
Intervention: T-piece breathing (30 minutes)
Number of subjects: 12
Study 10084467 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol + beclomethasone dipropionate (BDP, 500 microg bid)
Number of subjects: 12
Study 10084467 — intervention group
Group type: COMPARATOR
Intervention: placebo + BDP
Number of subjects: 12
Study 7484878 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) plus graduated compression stockings (GCS)
Number of subjects: 344
Study 7484878 — intervention group
Group type: COMPARATOR
Intervention: Graduated compression stockings (GCS) alone
Number of subjects: 344
Study 2099194 — intervention group
Group type: EXPERIMENTAL
Intervention: Genivir (DIP-253) 1% cream
Number of subjects: 100
Study 2099194 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 100
Study 6117063 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg/day)
Number of subjects: 24
Study 6117063 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (200 mg/day)
Number of subjects: 24
Study 6117063 — intervention group
Group type: COMPARATOR
Intervention: Acebutolol (400 mg/day)
Number of subjects: 24
Study 6117063 — intervention group
Group type: COMPARATOR
Intervention: Oxprenolol (160 mg/day)
Number of subjects: 24
Study 30820738 — intervention group
Group type: EXPERIMENTAL
Intervention: ocrelizumab 600 mg administered by intravenous infusion every 24 weeks
Number of subjects: 0
Study 30820738 — intervention group
Group type: COMPARATOR
Intervention: interferon (IFN) β‐1a 44 µg subcutaneous three times per week
Number of subjects: 0
Study 29976291 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 57
Study 29976291 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 57
Study 27814749 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-implant mandibular overdenture
Number of subjects: 0
Study 27814749 — intervention group
Group type: COMPARATOR
Intervention: Conventional complete denture
Number of subjects: 0
Study 24443820 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored weekly e-mail reminder (n = 175)
Number of subjects: 1337
Study 24443820 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized weekly e-mail reminder (n = 176)
Number of subjects: 1337
Study 24443820 — intervention group
Group type: EXPERIMENTAL
Intervention: No e-mail reminder (n = 175)
Number of subjects: 1337
Study 24443820 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (n = 180)
Number of subjects: 1337
Study 22042371 — intervention group
Group type: COMPARATOR
Intervention: Conjugated equine estrogen (CEE) alone
Number of subjects: 27347
Study 22042371 — intervention group
Group type: COMPARATOR
Intervention: Conjugated equine estrogen (CEE) plus medroxyprogesterone (MPA)
Number of subjects: 27347
Study 19395973 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol alone (1.5 mg kg(‐1))
Number of subjects: 60
Study 19395973 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tramadol (1 mg kg(‐1)) and paracetamol 1 g
Number of subjects: 60
Study 17484874 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir 450 mg every 8 hours
Number of subjects: 0
Study 17484874 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir 750 mg every 8 hours
Number of subjects: 0
Study 17484874 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir 1250 mg every 12 hours
Number of subjects: 0
Study 17484874 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir (all dosages)
Number of subjects: 0
Study 15234692 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 56
Study 15234692 — intervention group
Group type: COMPARATOR
Intervention: Bypass surgery
Number of subjects: 56
Study 11642016 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous administration of Tazocin (12 g/1.5 g a day)
Number of subjects: 0
Study 11642016 — intervention group
Group type: COMPARATOR
Intervention: Intermittent administration of Tazocin (three injections of 4 g/0.5 g a day)
Number of subjects: 0
Study 9738692 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 17
Study 9738692 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 17
Study 7802464 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly bolus injection of 5-FU and Leucovorin (A)
Number of subjects: 16
Study 7802464 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days continuous injection of 5-FU after bolus injection of Leucovorin (B)
Number of subjects: 16
Study 7802464 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days simultaneously continuous injection of 5-FU with Leucovorin (C)
Number of subjects: 16
Study 3132792 — intervention group
Group type: EXPERIMENTAL
Intervention: buserelin (D‐Ser(TBU)6‐GnRH ethylamide)
Number of subjects: 19
Study 3132792 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 19
Study 30268114 — intervention group
Group type: EXPERIMENTAL
Intervention: Crowdsourced intervention including multimedia (two videos and two images) and participatory component (inviting suggestions for improvement)
Number of subjects: 700
Study 30268114 — intervention group
Group type: COMPARATOR
Intervention: Control group (no images or videos, no invitation to submit suggestions)
Number of subjects: 700
Study 30268114 — intervention group
Group type: EXPERIMENTAL
Intervention: Crowdsourced intervention
Number of subjects: 700
Study 30268114 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 700
Study 27325850 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 129
Study 27325850 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 129
Study 24825251 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA)
Number of subjects: 32
Study 24825251 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 32
Study 23106926 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone or buprenorphine exposure in utero
Number of subjects: 131
Study 23106926 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal weight at delivery
Number of subjects: 131
Study 23106926 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated gestational age (EGA)
Number of subjects: 131
Study 23106926 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal use of selective serotonin re‐uptake inhibitors (SSRIs)
Number of subjects: 131
Study 23106926 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery type (vaginal delivery)
Number of subjects: 131
Study 23106926 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant birthweight
Number of subjects: 131
Study 23106926 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal nicotine use at delivery
Number of subjects: 131
Study 23106926 — intervention group
Group type: EXPERIMENTAL
Intervention: Days of maternal study medication received
Number of subjects: 131
Study 23106926 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal use of SSRIs and higher nicotine use
Number of subjects: 131
Study 23106926 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of treatment for NAS
Number of subjects: 131
Study 20051692 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 million IU of recombinant interleukin-2 (rIL-2) left in the cysts after transvaginal ultrasound-guided drainage (group I) once
Number of subjects: 25
Study 20051692 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 million IU of recombinant interleukin-2 (rIL-2) left in the cysts after transvaginal ultrasound-guided drainage (group II) twice
Number of subjects: 25
Study 18660565 — intervention group
Group type: EXPERIMENTAL
Intervention: H‐CAD intervention (1 month, 30 minutes per day, 5 days a week)
Number of subjects: 81
Study 18660565 — intervention group
Group type: EXPERIMENTAL
Intervention: H‐CAD intervention
Number of subjects: 81
Study 18660565 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 81
Study 15635270 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block with lidocaine
Number of subjects: 60
Study 15635270 — intervention group
Group type: COMPARATOR
Intervention: Steroid injection
Number of subjects: 60
Study 12560431 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 287
Study 12560431 — intervention group
Group type: COMPARATOR
Intervention: No diabetes
Number of subjects: 287
Study 10225069 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion of morphine with bupivacaine (0.10‐0.28 mg.kg‐1.h‐1)
Number of subjects: 52
Study 10225069 — intervention group
Group type: COMPARATOR
Intervention: Epidural infusion of morphine with lidocaine (0.44‐0.98 mg.kg‐1.h‐1)
Number of subjects: 52
Study 10225069 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study 8952812 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide diuretics alone or in combination with beta blockers
Number of subjects: 0
Study 8952812 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide diuretics
Number of subjects: 0
Study 8952812 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide diuretics in combination with beta blockers or ACE inhibitors
Number of subjects: 0
Study 8519216 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of 0.5 mg captopril (n = 16)
Number of subjects: 30
Study 8519216 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 14)
Number of subjects: 30
Study 3027837 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of itraconazole per day for five days
Number of subjects: 42
Study 3027837 — intervention group
Group type: COMPARATOR
Intervention: 100 mg of itraconazole per day for five days
Number of subjects: 42
Study 31140940 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of orally administered alpha lipoic acid (ALA) once a day during the 12‐week period
Number of subjects: 100
Study 31140940 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 100
Study 28166828 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological support (counselling, relaxation, mindfulness-based exercises, and possibly neuropsychological rehabilitation) delivered via 4-8 meetings.
Number of subjects: 150
Study 28166828 — intervention group
Group type: COMPARATOR
Intervention: Standard care (educational videos related to disease management).
Number of subjects: 150
Study 26535612 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry capsules
Number of subjects: 49
Study 26535612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 24130286 — intervention group
Group type: EXPERIMENTAL
Intervention: InfoClinique
Number of subjects: 15
Study 24130286 — intervention group
Group type: EXPERIMENTAL
Intervention: Trip database
Number of subjects: 15
Study 24130286 — intervention group
Group type: COMPARATOR
Intervention: InfoClinique and Trip database
Number of subjects: 15
Study 21738622 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg daily for four weeks
Number of subjects: 80